BLOG

pharma's almanac

Epigenetic Regulation To Treat Acute Organ Injury And Chronic Liver Diseases

DURECT Corporation is advancing an epigenetic regulator program aimed at developing products to treat acute AH and nonalcoholic steatohepatitis (NASH), a type of nonalcoholic fatty liver disease. DURECT’s therapeutics in development have the potential to treat multiple organ injury and chronic liver diseases.